Related Experiment Video
Updated: Apr 11, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.2K
Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein
S Tani1, K Nagao2, A Hirayama2
1Department of Health Planning Center, Nihon University Hospital, Tokyo Japan.
Drug Research
|May 27, 2015
Summary
Mitiglinide/voglibose and glimepiride treatments differently affect low-density lipoprotein (LDL) metabolism in type-2 diabetes patients. These changes may relate to blood glucose fluctuations experienced during treatment.
Area of Science:
- Endocrinology
- Metabolic Syndrome
- Pharmacology
Background:
- Type-2 diabetes mellitus (T2DM) management often involves combination therapies to achieve glycemic control.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used, but some patients require additional agents.
- Low-density lipoprotein (LDL) particle size and heterogeneity are increasingly recognized as cardiovascular risk factors.
Purpose of the Study:
- To compare the impact of a fixed-dose combination of mitiglinide/voglibose versus glimepiride on LDL heterogeneity.
- To evaluate these effects in type-2 diabetic patients with suboptimal glycemic control despite DPP-4 inhibitor therapy.
Main Methods:
- An open-label pilot study randomized 30 type-2 diabetic patients to receive either mitiglinide/voglibose (n=14) or glimepiride (n=16).
- Patients had unstable glycemic control while on DPP-4 inhibitors.
- LDL heterogeneity markers, including LDL cholesterol (LDL-C) and small-dense (sd) LDL, were assessed.
Main Results:
- Glimepiride significantly reduced LDL-C and sd-LDL levels.
- Mitiglinide/voglibose significantly decreased sd-LDL levels and increased LDL-C/apoB, an indicator of LDL particle size.
- Fasting blood glucose reduction was greater with glimepiride, while HbA1c reduction trended higher with mitiglinide/voglibose.
Conclusions:
- Mitiglinide/voglibose and glimepiride exert distinct effects on LDL metabolism when added to DPP-4 inhibitor therapy.
- These differential effects on LDL heterogeneity may be linked to variations in blood glucose fluctuations induced by the treatments.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
901
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
901
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
981
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
981
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
981
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
981
01:24Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K